Last reviewed 2026-05-26 · How we verify

AMOSULALOL

Phase 2 active Small molecule ✓ Verified May 2026

AMOSULALOL is a amosulalol drug. It is currently in Phase 2 development.

Amosulalol works by blocking the action of certain enzymes that regulate heart rate and blood pressure.

Amosulalol is a small molecule drug in the amosulalol class, but its target and approved indications are unknown. Its bioavailability is high at 99%. The commercial status of amosulalol is unclear, with unknown generic manufacturers and patent status. Further information on its pharmacokinetics, such as half-life, is also unavailable. As a result, key safety considerations and clinical use cannot be fully assessed.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AMOSULALOL
Drug class	amosulalol
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of it like a brake pedal in a car - amosulalol helps slow down the heart rate and reduce blood pressure by blocking the enzymes that normally speed it up. This can help people with certain heart conditions or high blood pressure. By reducing the workload on the heart, amosulalol can help prevent complications and improve overall cardiovascular health.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AMOSULALOL CI brief — competitive landscape report
AMOSULALOL updates RSS · CI watch RSS

Frequently asked questions about AMOSULALOL

What is AMOSULALOL?

AMOSULALOL is a amosulalol drug.

How does AMOSULALOL work?

Amosulalol works by blocking the action of certain enzymes that regulate heart rate and blood pressure.

What drug class is AMOSULALOL in?

AMOSULALOL belongs to the amosulalol class. See all amosulalol drugs at /class/amosulalol.

What development phase is AMOSULALOL in?

AMOSULALOL is in Phase 2.

Drug class: All amosulalol drugs
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing